Jagsonpal Pharmaceuticals Limited has published newspaper advertisements announcing its audited financial results for the quarter and financial year ended March 31, 2026, in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company declared an impressive 200% dividend, demonstrating strong commitment to shareholder wealth creation.

Strong Financial Performance Across Key Metrics

The pharmaceutical company reported robust growth across all major financial parameters for FY26. The performance highlights showcase the company's operational strength and market positioning.

Regulatory Compliance and Communication

The company fulfilled its regulatory obligations by publishing the financial results advertisement in Business Standard newspapers in both English and Hindi editions on April 29, 2026. Company Secretary and Compliance Officer Pratham Rawal signed the communication to stock exchanges, confirming the publication of these extracts.

Dividend Declaration Strengthens Shareholder Value

The declaration of a 200% dividend represents a significant return to shareholders, reflecting the company's strong cash position and confidence in future prospects. This substantial dividend payout underscores management's commitment to sharing the benefits of improved financial performance with investors.

Corporate Information and Market Presence

Jagsonpal Pharmaceuticals operates from its corporate office in Gurugram, Haryana, and maintains its registered office in New Delhi. The company trades on both major Indian stock exchanges - BSE (Scrip Code: 507789) and NSE (Symbol: JAGSNPHARM). The company also runs the "My Sakhi" CSR initiative, demonstrating its commitment to social responsibility alongside business growth.

Jagsonpal Pharmaceuticals Limited has announced a buyback of 16,00,000 fully paid-up equity shares at ₹250 per share, aggregating to ₹40,00,00,000. The Board of Directors approved the proposal on March 12, 2026, and shareholders approved it through postal ballot on April 24, 2026. The public announcement was published on April 29, 2026.

The buyback represents 2.39% of the total paid-up equity share capital and 18.35% of the aggregate of paid-up equity share capital and free reserves as of March 31, 2025. The offer will be executed through the tender offer route on a proportionate basis, with 15% of the shares reserved for small shareholders or the actual number of shares entitled to small shareholders based on their shareholding, whichever is higher.

Buyback Details

Key Provisions

The promoters and promoter group, holding 67.20% of the total equity shares, have confirmed they will not participate in the buyback. The buyback price of ₹250 per share represents a premium of approximately 39-48% over various market price benchmarks, including volume-weighted average prices and closing prices on BSE and NSE during periods preceding the intimation date.

The company has appointed Centrum Capital Limited as the Manager to the Buyback. A Buyback Committee has been constituted with Mr. Debasis Nandy, Mr. Manish Gupta, and Mr. Prithipal Singh Kochhar as members to oversee the implementation process. Mr. Pratham Rawal, Company Secretary, has been designated as the Compliance Officer for the buyback.

Financial Position and Funding

The funds for the buyback will be sourced from the company's free reserves, securities premium account, and internal accruals. The company confirms it is a debt-free entity with strong cash flows, having generated over ₹142 crores in free cash between FY22 and FY25. As of December 31, 2025, the company reported free cash of ₹176 crores, including ₹30 crore generated in Q3FY26.

The buyback is expected to improve return on equity by reducing the equity base and enhance earnings per share. The company estimates the transaction will lead to approximately 400 basis points improvement in Return on Capital Employed (ROCE). The buyback will be completed within 12 months from the date of passing the special resolution.